Can a gout drug help lung cancer treatment reach the brain?
NCT ID NCT07485452
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding febuxostat (a gout medicine) to the standard lung cancer drug osimertinib can increase the amount of osimertinib that reaches the brain. It involves 7 adults with a specific type of advanced lung cancer who are already taking osimertinib. Researchers will measure drug levels in spinal fluid before and after adding febuxostat to see if the combination works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Maastricht UMC+
RECRUITINGMaastricht, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Netherlands Cancer Institute
NOT_YET_RECRUITINGAmsterdam, Netherlands